Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 6/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945045 | 0.89 | PIM1 (0.54) | F2RL3PIM1TGFBR1MAPK14FYN | |
| SCHEMBL1944269 | 0.89 | MAPT (0.46) | F2RL3PIM1TGFBR1MAPK14NAMPT | |
| SCHEMBL1945626 | 0.89 | F2RL3 (0.47) | F2RL3PIM1TGFBR1MAPK14NPC1 | |
| SCHEMBL1945070 | 0.87 | NAMPT (0.49) | F2RL3PIM1TGFBR1MAPK14NAMPT | |
| SCHEMBL1946623 | 0.86 | RAB9A (0.47) | F2RL3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1944164 | 0.85 | F2RL3 (0.53) | F2RL3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1944019 | 0.83 | F2RL3 (0.53) | F2RL3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1945473 | 0.83 | RAB9A (0.49) | F2RL3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1946966 | 0.83 | CYP3A4 (0.56) | F2RL3PIM1TGFBR1MAPK14FYN | |
| SCHEMBL1946805 | 0.83 | RAB9A (0.53) | F2RL3MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | F2RL3 1121/4885PIM1 72/4885TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.